• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

考科蓝关于中医药的系统评价:关键在于证据的数量还是质量?

Cochrane systematic reviews on traditional Chinese medicine: What matters-the quantity or quality of evidence?

作者信息

Dai Zeqi, Liao Xing, Wieland L Susan, Hu Jing, Wang Yongyan, Kim Tae-Hun, Liu Jian-Ping, Zhan Siyan, Robinson Nicola

机构信息

Center for Evidence Based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China; China Center for Evidence Based Traditional Chinese Medicine, Beijing 100700, China.

Center for Evidence Based Chinese Medicine, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.

出版信息

Phytomedicine. 2022 Apr;98:153921. doi: 10.1016/j.phymed.2021.153921. Epub 2022 Jan 10.

DOI:10.1016/j.phymed.2021.153921
PMID:35104758
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9741948/
Abstract

BACKGROUND

Systematic reviews on traditional Chinese medicine (TCM) are constantly increasing. However, if these reviews are to be of practical value, the evidence needs to be relevant, valid, and adequately reported. Cochrane Systematic Reviews (CSRs) are considered as high-quality systematic reviews that can inform health care decision making. Our aim was to provide an overview of the scope, findings, quality and impact of CSRs on the benefits and harms associated with TCM interventions for the treatment and prevention of disease to provide new information for clinical practice and future research.

METHODS

The Cochrane Database of Systematic Reviews was searched up to May 2021, and descriptive characteristics were extracted. The correspondence between the questions asked in the CSRs and the available evidence, conclusions and certainty of findings (according to GRADE assessment), methodological quality (AMSTAR 2), and impact (Altmetric Attention Score [AAS], total citations by guideline, and total citations in Web of Science [WoS]) of CSRs were extracted. Tabular and graphical summaries of these descriptive characteristics were constructed.

RESULTS

Of 104 CSRs on TCM identified, 70 diseases belonged to 16 disease systems and contained 1642 primary studies with 157,943 participants. Interventions included Chinese herbal medicine (n = 70), acupuncture (n = 28), TCM exercises (n = 4), and moxibustion (n = 2). Among 1642 primary studies, 662 studies included an intervention group treated with at least one TCM therapy and 980 studies included a combination of therapies. Promising outcomes from the 104 CSRs were divided into endpoint outcomes (34 diseases), doctor- or patient-reported outcomes (27 diseases), and surrogate outcomes (37 diseases). Despite the presence of promising outcomes, only 5/104 CSRs drew overall positive conclusions, 42 CSRs concluded the evidence was insufficient, and 54 failed to draw firm conclusions. GRADE assessments were reported in 41.3% of the CSRs, and the ratings were mostly low or very low. Comparing the questions asked and results obtained, there was frequently a lack of information about specific outcomes. Only 16 CSRs obtained results for all outcomes listed in the methods section. According to AMSTAR 2, 51 CSRs (49.0%) were of low quality. The total number of citations in the WoS was 2135 (mean ± SD: 20.8 ± 21.2), and 38.5% of the CSRs had been cited in guidelines 95 times.

CONCLUSION

Although TCM is commonly used, evidence of its effectiveness remains largely inconclusive. Rigorous high-quality trials are needed to support the performance of high-quality reviews and to increase the evidence base. It is critical to emphasize quality over quantity in future TCM research.

摘要

背景

关于传统中医(TCM)的系统评价不断增加。然而,要使这些评价具有实际价值,证据需要相关、有效且得到充分报告。Cochrane系统评价(CSRs)被视为高质量的系统评价,可为医疗保健决策提供依据。我们的目的是概述CSRs关于中医干预治疗和预防疾病的益处和危害的范围、结果、质量和影响,为临床实践和未来研究提供新信息。

方法

检索截至2021年5月的Cochrane系统评价数据库,并提取描述性特征。提取CSRs中提出的问题与现有证据、结论和研究结果的确定性(根据GRADE评估)、方法学质量(AMSTAR 2)以及CSRs的影响(Altmetric关注度得分[AAS]、指南总引用次数和科学引文索引[WoS]中的总引用次数)之间的对应关系。构建这些描述性特征的表格和图形摘要。

结果

在确定的104篇关于中医的CSRs中,70种疾病属于16个疾病系统,包含1642项原始研究,涉及157,943名参与者。干预措施包括中药(n = 70)、针灸(n = 28)、中医功法(n = 4)和艾灸(n = 2)。在1642项原始研究中,662项研究包括至少一种中医治疗的干预组,98项研究包括联合治疗。104篇CSRs中显示有前景的结果分为终点结局(34种疾病)、医生或患者报告的结局(27种疾病)和替代结局(37种疾病)。尽管存在有前景的结果,但只有5/104篇CSRs得出总体阳性结论,42篇CSRs得出证据不足的结论,54篇未能得出明确结论。41.3%的CSRs报告了GRADE评估,评级大多为低或极低。比较提出的问题和获得的结果,经常缺乏关于特定结局的信息。只有16篇CSRs获得了方法部分列出的所有结局的结果。根据AMSTAR 2,51篇CSRs(49.0%)质量较低。WoS中的总引用次数为2135次(均值±标准差:20.8 ± 21.2),38.5%的CSRs在指南中被引用95次。

结论

尽管中医被广泛使用,但其有效性的证据在很大程度上仍不明确。需要严格的高质量试验来支持高质量评价的开展并增加证据基础。在未来的中医研究中,强调质量而非数量至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/0992fc95cddb/nihms-1852553-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/f490e17fa1d4/nihms-1852553-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/8c75003fb8a0/nihms-1852553-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/9a99f86eb010/nihms-1852553-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/b9ccb00ebd29/nihms-1852553-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/7da3200df5aa/nihms-1852553-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/0992fc95cddb/nihms-1852553-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/f490e17fa1d4/nihms-1852553-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/8c75003fb8a0/nihms-1852553-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/9a99f86eb010/nihms-1852553-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/b9ccb00ebd29/nihms-1852553-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/7da3200df5aa/nihms-1852553-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c057/9741948/0992fc95cddb/nihms-1852553-f0006.jpg

相似文献

1
Cochrane systematic reviews on traditional Chinese medicine: What matters-the quantity or quality of evidence?考科蓝关于中医药的系统评价:关键在于证据的数量还是质量?
Phytomedicine. 2022 Apr;98:153921. doi: 10.1016/j.phymed.2021.153921. Epub 2022 Jan 10.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
4
The use of GRADE approach in Cochrane reviews of TCM was insufficient: a cross-sectional survey.在 Cochrane 中医药评价中 GRADE 方法的使用不足:一项横断面调查。
J Clin Epidemiol. 2022 Feb;142:1-9. doi: 10.1016/j.jclinepi.2021.11.004. Epub 2021 Nov 6.
5
Evidence from the Cochrane Collaboration for Traditional Chinese Medicine therapies.来自循证医学协作网关于中医药疗法的证据。
J Altern Complement Med. 2009 Sep;15(9):1001-14. doi: 10.1089/acm.2008.0414.
6
Traditional Chinese medicine for insomnia: Recommendation mapping of the global clinical guidelines.中医药治疗失眠症:全球临床指南的推荐图谱。
J Ethnopharmacol. 2024 Mar 25;322:117601. doi: 10.1016/j.jep.2023.117601. Epub 2023 Dec 18.
7
Efficacy and safety of traditional Chinese medicine adjuvant therapy for severe pneumonia: evidence mapping of the randomized controlled trials, systematic reviews, and meta-analyses.中药辅助治疗重症肺炎的疗效与安全性:随机对照试验、系统评价和荟萃分析的证据图谱
Front Pharmacol. 2023 Sep 29;14:1227436. doi: 10.3389/fphar.2023.1227436. eCollection 2023.
8
Traditional Chinese medicine treatment for COVID-19: An overview of systematic reviews and meta-analyses.中医药治疗 COVID-19:系统评价和荟萃分析概述。
J Integr Med. 2022 Sep;20(5):416-426. doi: 10.1016/j.joim.2022.06.006. Epub 2022 Jun 24.
9
Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.儿童哮喘急性加重期治疗升级的干预措施:Cochrane系统评价综述
Cochrane Database Syst Rev. 2020 Aug 5;8(8):CD012977. doi: 10.1002/14651858.CD012977.pub2.
10
Chinese medicine formulas for nonalcoholic fatty liver disease: Overview of systematic reviews.用于非酒精性脂肪性肝病的中药方剂:系统评价概述
World J Clin Cases. 2021 Jan 6;9(1):102-117. doi: 10.12998/wjcc.v9.i1.102.

引用本文的文献

1
Koidzumi modulates human colonic motility via ICCs pacemaker suppression and cAMP/ATP-sensitive K⁺ channel pathways.小泉通过抑制肠肌间神经丛起搏细胞和环磷酸腺苷/三磷酸腺苷敏感性钾通道途径来调节人类结肠运动。
Int J Med Sci. 2025 Jul 24;22(13):3412-3421. doi: 10.7150/ijms.116169. eCollection 2025.
2
Bridging traditional Chinese medicine and Alzheimer's disease: the pivotal role of gut microbiota in multitarget therapeutic mechanisms.中医与阿尔茨海默病的桥梁:肠道微生物群在多靶点治疗机制中的关键作用
Front Pharmacol. 2025 Jun 27;16:1630205. doi: 10.3389/fphar.2025.1630205. eCollection 2025.
3
Glucocorticoid Discontinuation in Patients with Rheumatoid Arthritis under Background of Chinese Medicine: Challenges and Potentials Coexist.

本文引用的文献

1
Detection of an anti-angina therapeutic module in the effective population treated by a multi-target drug Danhong injection: a randomized trial.丹红注射液治疗有效人群中抗心绞痛治疗模块的检测:一项随机试验。
Signal Transduct Target Ther. 2021 Sep 1;6(1):329. doi: 10.1038/s41392-021-00741-x.
2
Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome : A Randomized Trial.针刺治疗慢性前列腺炎/慢性骨盆疼痛综合征的疗效:一项随机试验。
Ann Intern Med. 2021 Oct;174(10):1357-1366. doi: 10.7326/M21-1814. Epub 2021 Aug 17.
3
Effects of Tai Chi or Conventional Exercise on Central Obesity in Middle-Aged and Older Adults : A Three-Group Randomized Controlled Trial.
中医药背景下类风湿关节炎患者糖皮质激素停药:挑战与潜力并存
Chin J Integr Med. 2025 Jul;31(7):581-589. doi: 10.1007/s11655-025-4212-3. Epub 2025 Jun 24.
4
Zuojin Pill enhances gastrointestinal motility by modulating the pacemaker potentials in interstitial cells of Cajal through multiple signaling pathways.左金丸通过多种信号通路调节 Cajal 间质细胞的起搏电位来增强胃肠动力。
Int J Med Sci. 2024 Oct 28;21(15):2883-2896. doi: 10.7150/ijms.103507. eCollection 2024.
5
Modulation of the Mas-Related G Protein-Coupled Receptor X2 (MRGPRX2) by Xenobiotic Compounds and Its Relevance to Human Diseases.异源生物化合物对Mas相关G蛋白偶联受体X2(MRGPRX2)的调节作用及其与人类疾病的相关性。
J Xenobiot. 2024 Mar 13;14(1):380-403. doi: 10.3390/jox14010024.
6
Chinese herbal injections in combination with radiotherapy for advanced pancreatic cancer: A systematic review and network meta-analysis.中药注射剂联合放疗治疗晚期胰腺癌:一项系统评价和网状Meta分析
Integr Med Res. 2023 Dec;12(4):101004. doi: 10.1016/j.imr.2023.101004. Epub 2023 Oct 28.
7
Efficacy and safety of non-pharmacological therapy under the guidance of TCM theory in the treatment of anxiety in patients with myocardial infarction: A protocol for systematic review and meta-analysis.基于中医理论的非药物疗法治疗心肌梗死患者焦虑的疗效和安全性的系统评价和荟萃分析方案。
PLoS One. 2023 Jul 6;18(7):e0288154. doi: 10.1371/journal.pone.0288154. eCollection 2023.
8
, : Toward the modernization of traditional Chinese medicine.迈向中医药现代化。
Front Neurosci. 2022 Nov 10;16:1057817. doi: 10.3389/fnins.2022.1057817. eCollection 2022.
太极拳或常规运动对中年及以上人群中心型肥胖的影响:三臂随机对照试验。
Ann Intern Med. 2021 Aug;174(8):1050-1057. doi: 10.7326/M20-7014. Epub 2021 Jun 1.
4
The quality of Cochrane systematic reviews of acupuncture: an overview.针刺的 Cochrane 系统评价的质量:概述。
BMC Complement Med Ther. 2020 Oct 14;20(1):307. doi: 10.1186/s12906-020-03099-9.
5
Chinese Medicine, Which Targets Body's Response State, Is An Effective Way to Treat Epidemic Infectious Diseases.中医针对人体的反应状态,是治疗传染病的有效方法。
Chin J Integr Med. 2022 Feb;28(2):168-175. doi: 10.1007/s11655-020-3324-z. Epub 2020 Oct 10.
6
The birth of artemisinin.青蒿素的诞生。
Pharmacol Ther. 2020 Dec;216:107658. doi: 10.1016/j.pharmthera.2020.107658. Epub 2020 Aug 8.
7
Less is more, now more than ever.少即是多,如今比以往任何时候都更是如此。
BMJ Qual Saf. 2021 Jan;30(1):56-58. doi: 10.1136/bmjqs-2020-011444. Epub 2020 May 22.
8
China is promoting coronavirus treatments based on unproven traditional medicines.中国正在推广基于未经证实的传统药物的新冠病毒治疗方法。
Nature. 2020 May 6. doi: 10.1038/d41586-020-01284-x.
9
Correlation of Altmetric Attention Score and Citations for High-Impact General Medicine Journals: a Cross-sectional Study.高影响力普通医学期刊的替代计量关注度得分与引用率的相关性:一项横断面研究。
J Gen Intern Med. 2019 Jun;34(6):825-827. doi: 10.1007/s11606-019-04838-6.
10
Moxibustion for alleviating side effects of chemotherapy or radiotherapy in people with cancer.艾灸缓解癌症患者化疗或放疗的副作用
Cochrane Database Syst Rev. 2018 Nov 13;11(11):CD010559. doi: 10.1002/14651858.CD010559.pub2.